Fosaprepitant

Evidence Level: L5

Predicted Indications: 10

Fosaprepitant

Pharmacist Assessment Report

One-Sentence Summary

Fosaprepitant is an intravenous prodrug of aprepitant, a substance P/NK1 receptor antagonist. It is marketed in Australia as Emend IV, although the data compiled for this report do not include its approved indication text. The TxGNN model predicts it may be effective for nephrogenic syndrome of inappropriate antidiuresis (NSIAD), but there are currently 0 clinical trials and 0 publications supporting this prediction. This is a model-only prediction.

Quick Overview

Item	Content
Original Indication	Not available in the data compiled for this report (the ARTG entry has no indication text)
Predicted New Indication	Nephrogenic syndrome of inappropriate antidiuresis
TxGNN Prediction Score	0.9992
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data are not available in the data compiled for this report. Based on known information, fosaprepitant is a prodrug of aprepitant, which blocks NK1 receptors (the receptors for substance P).

NSIAD is caused by gain-of-function variants of the vasopressin V2 receptor, which lead to water retention and low blood sodium. No established link connects NK1 receptor antagonism to this mechanism. Any connection, for example indirect modulation of water balance through neuropeptide signalling, is speculative.

The high TxGNN score therefore comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It should be treated as a hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for NSIAD.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 11103J	Emend IV	Powder for I.V. infusion 150 mg	Not stated in the data compiled

Cytotoxicity

Fosaprepitant is a supportive-care antiemetic, not an antineoplastic agent, so no cytotoxicity assessment applies.

Safety Considerations

Contraindications (model signal, not label text): The TxGNN model (deep learning) flags a possible contraindication with liver failure. This is not derived from the product label and may reflect similarities the model learned between related diseases, not biological evidence. It should be verified against the TGA-approved Product Information (PI).
Drug Interactions: 100 interactions were identified in total. The following are examples from the DDInter source.
- Major: eliglustat, naloxegol
- Moderate: corticosteroids (dexamethasone, hydrocortisone, betamethasone, budesonide, triamcinolone), clarithromycin, cimetidine, proton pump inhibitors (rabeprazole, lansoprazole), miconazole, pioglitazone, glimepiride, nateglinide, saxagliptin, alosetron, dronabinol, naldemedine

Please refer to the TGA-approved Product Information (PI) for the full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on model output alone (L5). There are no trials or publications, and no plausible mechanistic link between NK1 antagonism and the V2 receptor gain-of-function that causes NSIAD.

To proceed, the following is needed:

Mechanism of action data (for example from DrugBank) and a testable mechanistic hypothesis for NSIAD
The approved indication text and the TGA Product Information, including warnings and contraindications, to allow safety screening
Preclinical or case-level evidence of an effect on water balance or vasopressin signalling
Review of the liver failure contraindication signal and the CYP3A4-related interaction burden for the target population

Other Predicted Indications (Context)

The other top-ranked predictions are also model-only (L5) with no supporting trials or literature, and all carry a Hold recommendation. They are pneumocystosis, leprosy, cryptococcal meningitis, multiple endocrine neoplasia, intracranial abscess, Plasmodium falciparum malaria, echinococcosis and hyperargininemia. The exception is retinitis (rank 7, score 0.9968), which has L4 preclinical support from one mouse study (PMID 32058829, 2021, Ocular Immunology and Inflammation). That study showed fosaprepitant blocked UVR-B-induced NK1R expression in ocular tissues. It used a UV-induced injury model and not clinical retinitis, so its translational relevance is uncertain. It is classed as a research question and not a development candidate.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.